Familial risk of melanoma and links with other cancers

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1 Shaikh WR, Weinstock MA, Halpern AC, Oliveria SA, Geller AC, Dusza SW. The characterization and potential impact of melanoma cases with unknown thickness in the United States’ Surveillance, Epidemiology, and End Results Program, 1989–2008. Cancer Epidemiol. 37(1), 64–70 (2013).
  MedlineGoogle Scholar
• 2 Forsea AM, Del Marmol V, de Vries E, Bailey EE, Geller AC. Melanoma incidence and mortality in Europe: new estimates, persistent disparities. Br. J. Dermatol. 167(5), 1124–1130 (2012).
  Medline CASGoogle Scholar
• 3 Giblin AV, Thomas JM. Incidence, mortality and survival in cutaneous melanoma. J. Plast. Reconstr. Aesthet. Surg. 60(1), 32–40 (2007).
  MedlineGoogle Scholar
• 4 Howlader N NA, Krapcho M, Garshell J et al. SEER Cancer Statistics Review, 1975–2011. National Cancer Institute, Bethesda, MD, USA. http://seer.cancer.gov/csr/1975_2011/.
  Google Scholar
• 5 Meyle KD, Guldberg P. Genetic risk factors for melanoma. Hum. Genet. 126(4), 499–510 (2009).
  Medline CASGoogle Scholar
• 6 Marzuka-Alcala A, Gabree MJ, Tsao H. Melanoma susceptibility genes and risk assessment. Methods Mol. Biol. 1102, 381–393 (2014).•• This is a good review article about the molecular pathways and pathogenesis of genes implicated in melanoma and associated tumors.
  Medline CASGoogle Scholar
• 7 Newton Bishop JA, Bishop DT. The genetics of susceptibility to cutaneous melanoma. Drugs Today (Barcelona). 41(3), 193–203 (2005).
  Medline CASGoogle Scholar
• 8 Fargnoli MC, Argenziano G, Zalaudek I, Peris K. High- and low-penetrance cutaneous melanoma susceptibility genes. Expert Rev. Anticancer Ther. 6(5), 657–670 (2006).
  Medline CASGoogle Scholar
• 9 Mehnert JM, Kluger HM. Driver mutations in melanoma: lessons learned from bench-to-bedside studies. Curr. Oncol. Rep. 14(5), 449–457, 2012.
  Medline CASGoogle Scholar
• 10 UV light accelerates melanoma metastasis. Cancer Discov. 4(6), 625–626 (2014).
  MedlineGoogle Scholar
• 11 Ragnarsson-Olding BK. Primary malignant melanoma of the vulva – an aggressive tumor for modeling the genesis of non-UV light-associated melanomas. Acta Oncol. 43(5), 421–435 (2004).
  MedlineGoogle Scholar
• 12 Ward KA, Lazovich D, Hordinsky MK. Germline melanoma susceptibility and prognostic genes: a review of the literature. J. Am. Acad. Dermatol. 67(5), 1055–1067 (2012).
  MedlineGoogle Scholar
• 13 Goldstein AM, Chan M, Harland M et al. Features associated with germline CDKN2A mutations: a GenoMEL study of melanoma-prone families from three continents. J. Med. Genet. 44(2), 99–106 (2007).• Provides an overview of the epidemiology of CDKN2A, and reviews tumors associated with this gene mutation.
  Medline CASGoogle Scholar
• 14 Helsing P, Nymoen DA, Ariansen S et al. Population-based prevalence of CDKN2A and CDK4 mutations in patients with multiple primary melanomas. Genes Chromosomes Cancer 47(2), 175–184 (2008).
  Medline CASGoogle Scholar
• 15 Hashemi J, Platz A, Ueno T, Stierner U, Ringborg U, Hansson J. CDKN2A germ-line mutations in individuals with multiple cutaneous melanomas. Cancer Res. 60(24), 6864–6867 (2000).
  Medline CASGoogle Scholar
• 16 Bishop JN, Harland M, Randerson-Moor J, Bishop DT. Management of familial melanoma. Lancet Oncol. 8(1), 46–54 (2007).
  Medline CASGoogle Scholar
• 17 Puig-Butille JA, Escamez MJ, Garcia-Garcia F et al. Capturing the biological impact of CDKN2A and MC1R genes as an early predisposing event in melanoma and non-melanoma skin cancer. Oncotarget 5(6), 1439–1451 (2014).
  MedlineGoogle Scholar
• 18 Hill VK, Gartner JJ, Samuels Y, Goldstein AM. The genetics of melanoma: recent advances. Annu. Rev. Genomics Hum. Genet. 14, 257–279 (2013).
  Medline CASGoogle Scholar
• 19 Demenais F, Mohamdi H, Chaudru V et al. Association of MC1R variants and host phenotypes with melanoma risk in CDKN2A mutation carriers: a GenoMEL study. J. Natl Cancer Inst. 102(20), 1568–1583 (2010).
  Medline CASGoogle Scholar
• 20 Bishop DT, Demenais F, Goldstein AM et al. Geographical variation in the penetrance of CDKN2A mutations for melanoma. J. Natl Cancer Inst. 94(12), 894–903 (2012).
  Google Scholar
• 21 Petersen GM, Vachon CM. Genetic epidemiology of melanoma: of consortia and conundrums. J. Natl Cancer Inst. 94(12), 872–873 (2002).
  MedlineGoogle Scholar
• 22 Moloney FJ, Guitera P, Coates E et al. Detection of primary melanoma in individuals at extreme high risk: a prospective 5-year follow-up study. JAMA Dermatol. 150(8), 819–827 (2014).
  MedlineGoogle Scholar
• 23 Bishop JA, Wachsmuth RC, Harland M et al. Genotype/phenotype and penetrance studies in melanoma families with germline CDKN2A mutations. J. Invest. Dermatol. 114(1), 28–33 (2000).
  Medline CASGoogle Scholar
• 24 Maubec E, Chaudru V, Mohamdi H et al. Familial melanoma: clinical factors associated with germline CDKN2A mutations according to the number of patients affected by melanoma in a family. J. Am. Acad. Dermatol. 67(6), 1257–1264 (2012).
  Medline CASGoogle Scholar
• 25 Lynch HT, Brand RE, Hogg D et al. Phenotypic variation in eight extended CDKN2A germline mutation familial atypical multiple mole melanoma-pancreatic carcinoma-prone families: the familial atypical mole melanoma-pancreatic carcinoma syndrome. Cancer 94(1), 84–96 (2002).
  Medline CASGoogle Scholar
• 26 Helgadottir H, Hoiom V, Jonsson G et al. High risk of tobacco-related cancers in CDKN2A mutation-positive melanoma families. J. Med. Genet. 51(8), 545–552 (2014).
  Medline CASGoogle Scholar
• 27 Potrony M, Puig-Butille JA, Aguilera P et al. Increased prevalence of lung, breast, and pancreatic cancers in addition to melanoma risk in families bearing the cyclin-dependent kinase inhibitor 2A mutation: implications for genetic counseling. J. Am. Acad. Dermatol. 71(5), 888–895 (2014).
  Medline CASGoogle Scholar
• 28 Sheppard KE, McArthur GA. The cell-cycle regulator CDK4: an emerging therapeutic target in melanoma. Clin. Cancer Res. 19(19), 5320–5328 (2013).
  Medline CASGoogle Scholar
• 29 Puntervoll HE, Yang XR, Vetti HH et al. Melanoma prone families with CDK4 germline mutation: phenotypic profile and associations with MC1R variants. J. Med. Genet. 50(4), 264–270 (2013).• Reviews phenotypic findings and associations based on the 17 families known to have a CDK4 mutation.
  Medline CASGoogle Scholar
• 30 Zuo L, Weger J, Yang Q et al. Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma. Nat. Genet. 12(1), 97–99 (1996).
  Medline CASGoogle Scholar
• 31 Pjanova D, Engele L, Randerson-Moor JA et al. CDKN2A and CDK4 variants in Latvian melanoma patients: analysis of a clinic-based population. Melanoma Res. 17(3), 185–191 (2007).
  MedlineGoogle Scholar
• 32 Moran A, O'Hara C, Khan S et al. Risk of cancer other than breast or ovarian in individuals with BRCA1 and BRCA2 mutations. Fam. Cancer 11(2), 235–242 (2012).
  Medline CASGoogle Scholar
• 33 Mai PL, Chatterjee N, Hartge P et al. Potential excess mortality in BRCA1/2 mutation carriers beyond breast, ovarian, prostate, and pancreatic cancers, and melanoma. PLoS ONE 4(3), e4812 (2009).
  MedlineGoogle Scholar
• 34 Scott RJ, Vajdic CM, Armstrong BK et al. BRCA2 mutations in a population-based series of patients with ocular melanoma. Int. J. Cancer 102(2), 188–191 (2002).
  Medline CASGoogle Scholar
• 35 Levy-Lahad E, Friedman E. Cancer risks among BRCA1 and BRCA2 mutation carriers. Br. J. Cancer 96(1), 11–15 (2007).• Provides a concise review of tumors associated with both BRCA1 and BRCA2 genes.
  Medline CASGoogle Scholar
• 36 Breast Cancer Linkage Consortium. Cancer risks in BRCA2 mutation carriers. J. Natl Cancer Inst. 91(15), 1310–1316 (1999).
  MedlineGoogle Scholar
• 37 Ismail IH, Davidson R, Gagne JP, Xu ZZ, Poirier GG, Hendzel MJ. Germline mutations in BAP1 impair its function in DNA double-strand break repair. Cancer Res. 74(16), 4282–4294 (2014).
  Medline CASGoogle Scholar
• 38 Wiesner T, Obenauf AC, Murali R et al. Germline mutations in BAP1 predispose to melanocytic tumors. Nat. Genet. 43(10), 1018–1021 (2011).
  Medline CASGoogle Scholar
• 39 Abdel-Rahman MH, Pilarski R, Cebulla CM et al. Germline BAP1 mutation predisposes to uveal melanoma, lung adenocarcinoma, meningioma, and other cancers. J. Med. Genet. 48(12), 856–859 (2011).
  Medline CASGoogle Scholar
• 40 Njauw CN, Kim I, Piris A et al. Germline BAP1 inactivation is preferentially associated with metastatic ocular melanoma and cutaneous-ocular melanoma families. PLoS ONE 7(4), e35295 (2012).
  Medline CASGoogle Scholar
• 41 Harbour JW, Onken MD, Roberson ED et al. Frequent mutation of BAP1 in metastasizing uveal melanomas. Science 330(6009), 1410–1413 (2010).•• Documents the association of BAP1 mutations with uveal melanoma. Provides a detailed discussion on how BAP1 was elucidating from families with uveal melanoma.
  Medline CASGoogle Scholar
• 42 Murali R, Wiesner T, Scolyer RA. Tumours associated with BAP1 mutations. Pathology 45(2), 116–126 (2013).
  Medline CASGoogle Scholar
• 43 Carbone M, Ferris LK, Baumann F et al. BAP1 cancer syndrome: malignant mesothelioma, uveal and cutaneous melanoma, and MBAITs. J. Transl. Med. 10, 179 (2012).
  Medline CASGoogle Scholar
• 44 Aoude LG, Wadt K, Bojesen A et al. A BAP1 mutation in a Danish family predisposes to uveal melanoma and other cancers. PLoS ONE 8(8), e72144 (2013).
  Medline CASGoogle Scholar
• 45 de la Fouchardiere A, Cabaret O, Savin L et al. Germline BAP1 mutations predispose also to multiple basal cell carcinomas. Clin. Genet. doi:10.1111/cge.12472. (2014) (Epub ahead of print).
  MedlineGoogle Scholar
• 46 Testa JR, Cheung M, Pei J et al. Germline BAP1 mutations predispose to malignant mesothelioma. Nat. Genet. 43(10), 1022–1025 (2011).
  Medline CASGoogle Scholar
• 47 Wiesner T, Fried I, Ulz P et al. Toward an improved definition of the tumor spectrum associated with BAP1 germline mutations. J. Clin. Oncol. 30(32), e337–e340 (2012).
  MedlineGoogle Scholar
• 48 Horn S, Figl A, Rachakonda PS et al. TERT promoter mutations in familial and sporadic melanoma. Science 339(6122), 959–961 (2013).•• Discusses the TERT mutation and its association with melanoma and other tumors.
  Medline CASGoogle Scholar
• 49 Huang FW, Hodis E, Xu MJ, Kryukov GV, Chin L, Garraway LA. Highly recurrent TERT promoter mutations in human melanoma. Science 339(6122), 957–959 (2013).•• Discusses the TERT mutation and its association with melanoma and other tumors.
  Medline CASGoogle Scholar
• 50 Griewank KG, Murali R, Schilling B et al. TERT promoter mutations are frequent in cutaneous basal cell carcinoma and squamous cell carcinoma. PLoS ONE 8(11), e80354 (2013).
  MedlineGoogle Scholar
• 51 Baird DM. Variation at the TERT locus and predisposition for cancer. Expert Rev. Mol. Med. 12, e16 (2010).
  MedlineGoogle Scholar
• 52 Bojesen SE, Pooley KA, Johnatty SE et al. Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nat. Genet. 45(4), 371–384, 384e1–2 (2013).
  Medline CASGoogle Scholar
• 53 Populo H, Boaventura P, Vinagre J et al. TERT promoter mutations in skin cancer: the effects of sun exposure and X-irradiation. J. Invest. Dermatol. 134(8), 2251–2257 (2014).
  Medline CASGoogle Scholar
• 54 Shi J, Yang XR, Ballew B et al. Rare missense variants in POT1 predispose to familial cutaneous malignant melanoma. Nat. Genet. 46(5), 482–486 (2014).•• Discusses the TERT mutation and its association with melanoma and other tumors.
  Medline CASGoogle Scholar
• 55 Robles-Espinoza CD, Harland M, Ramsay AJ et al. POT1 loss-of-function variants predispose to familial melanoma. Nat. Genet. 46(5), 478–481 (2014).•• Discusses the TERT mutation and its association with melanoma and other tumors.
  Medline CASGoogle Scholar
• 56 Ramsay AJ, Quesada V, Foronda M et al. POT1 mutations cause telomere dysfunction in chronic lymphocytic leukemia. Nat. Genet. 45(5), 526–530 (2013).
  Medline CASGoogle Scholar
• 57 Chang S. Cancer chromosomes going to POT1. Nat. Genet. 45(5), 473–475 (2013).
  Medline CASGoogle Scholar
• 58 Veronese L, Tournilhac O, Callanan M et al. Telomeres and chromosomal instability in chronic lymphocytic leukemia. Leukemia 27(2), 490–493 (2013).
  Medline CASGoogle Scholar